Racial, social, and clinical determinants of hepatocellular carcinoma surveillance

American Journal of Medicine

Volumn 128, Issue 1, 2015, Pages 90.e1-90.e7

  Singal, Amit G ^a,b,c   Li, Xilong ^b   Tiro, Jasmin ^b,c   Kandunoori, Pragathi ^a   Adams Huet, Beverley ^b   Nehra, Mahendra S ^a   Yopp, Adam ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Disparities; Liver cancer; Surveillance; Underuse

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CHILD PUGH SCORE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE SURVEILLANCE; FEMALE; HEALTH DISPARITY; HEPATITIS C VIRUS; HISPANIC; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; NONALCOHOLIC FATTY LIVER; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RACE; RETROSPECTIVE STUDY; SOCIOECONOMICS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEALTH SURVEY; LIVER NEOPLASMS; MIDDLE AGED; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GUIDELINE ADHERENCE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 85003048146     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.07.027     Document Type: Article

References (31)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
2. Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29: 285-292.
3. Singal AG, Pillai A, Tiro JA. Early Detection, Curative Treatment, and Survival Rates for HCC Surveillance in Patients with Cirrhosis: A meta-analysis. PLOS Medicine. 2014;11:e1001624.
4. Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl. 2009;15:859-868.
5. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2010;53:1-35.
7. Kanwal F, Kramer J, Asch SM, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8:709-717.
8. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47.
9. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154:85-93.
10. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52: 132-141.
11. Singal AG, Yopp A S, Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: A systematic review. J Gen Intern Med. 2012;27: 861-867.
12. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116: 1367-1377.
13. Decker KM, Harrison M, Chateau D. Influence of direct referrals on time to diagnosis after an abnormal breast screening result. Cancer Detect Prev. 2004;28:361-367.
14. Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: A population-based study. Clin Gastroenterol Hepatol. 2006;4:104-110; quiz 4e5.
15. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007;110: 660-669.
16. Du XL, Meyer TE, Franzini L. Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer. Cancer. 2007;109:2161-2170.
17. Lloyd SC, Harvey NR, Hebert JR, Daguise V, Williams D, Scott DB. Racial disparities in colon cancer. Primary care endoscopy as a tool to increase screening rates among minority patients. Cancer. 2007;109: 378-385.
18. Schueler KM, Chu PW, Smith-Bindman R. Factors associated with mammography utilization: A systematic quantitative review of the literature. J Womens Health (Larchmt). 2008;17:1477-1498.
19. Singal A, Volk M, Rakoski M, et al. Patient involvement is correlated with higher HCC surveillance in patients with cirrhosis. J Clin Gastroenterol. 2011;45:727-732.
20. Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol. 2013;47:e50-e54.
21. Vernon SW, Briss PA, Tiro JA, Warnecke RB. Some methodologic lessons learned from cancer screening research. Cancer. 2004;101: 1131-1145.
22. Taplin SH, Rodgers AB. Toward improving the quality of cancer care: Addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr. 2010;2010:3-10.
23. Singal AG, Mukherjee A, Joseph Elmunzer B, et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol. 2013;108:1723-1730.
24. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: Applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477.
25. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012;5: 1124-1130.
26. Singal AG, Marrero JA, Yopp AC. Screening Process Failures for Hepatocellular Carcinoma. J National Comprehensive Cancer Network. 2014;12:375-382.
27. Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of cancer care: The case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev. 2003;12:4-13.
28. Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108: 425-432.
29. Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38:703-712.
30. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183-2191.
31. Kanwal F, Hoang T, Kramer J, et al. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012;107:1512-1521.